Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children

To date, there is no consensus regarding palivizumab prophylaxis for respiratory syncytial virus infection. The purpose of this study is to assess the effectiveness of palivizumab prophylaxis to prevent respiratory syncytial virus-related infection consultations and hospitalizations in high-risk chi...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2021-06, Vol.17 (6), p.1867-1872
Main Authors: Viguria, Natividad, Navascués, Ana, Juanbeltz, Regina, Echeverría, Alberto, Ezpeleta, Carmen, Castilla, Jesús
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Antiviral Agents - therapeutic use
Child
effectiveness
Hospitalization
Humans
Infant
monoclonal antibody
palivizumab
Palivizumab - therapeutic use
Research Paper
Respiratory syncytial virus
Respiratory Syncytial Virus Infections
Spain
test-negative design
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To date, there is no consensus regarding palivizumab prophylaxis for respiratory syncytial virus infection. The purpose of this study is to assess the effectiveness of palivizumab prophylaxis to prevent respiratory syncytial virus-related infection consultations and hospitalizations in high-risk children
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.1080/21645515.2020.1843336